Over the past year there were no insider purchases at BioAge Labs, Inc.. Four insiders sold roughly $7.8 million instead.
Selling on its own is common and often pre-planned (10b5-1 plans, taxes, diversification), so it matters more when it is unusually heavy or broad.
No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters. 151 investment managers listed BIOA in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Barton Shane | Officer | Sell | 20,216 | $25.19 | $509K | SEC |
| Jul 1, 2026 | Barton Shane | Officer | Sell | 42,350 | $25.21 | $1.1M | SEC |
| Apr 3, 2026 | RUBIN PAUL D | Executive Officer | Sell | 8,820 | $17.81 | $157K | SEC |
| Mar 3, 2026 | RUBIN PAUL D | Executive Officer | Sell | 7,433 | $20.30 | $151K | SEC |
| Feb 3, 2026 | RUBIN PAUL D | Executive Officer | Sell | 7,433 | $18.75 | $139K | SEC |
| Jan 15, 2026 | GOLDSTEIN DOV A MD | CFO | Sell | 4,440 | $19.45 | $86K | SEC |
| Jan 15, 2026 | GOLDSTEIN DOV A MD | CFO | Sell | 11,663 | $20.54 | $240K | SEC |
| Jan 15, 2026 | GOLDSTEIN DOV A MD | CFO | Sell | 1,923 | $21.08 | $41K | SEC |
| Jan 15, 2026 | GOLDSTEIN DOV A MD | CFO | Sell | 8,974 | $18.43 | $165K | SEC |
| Jan 15, 2026 | Fortney Kristen | CEO | Sell | 233,107 | $18.12 | $4.2M | SEC |
| Jan 6, 2026 | RUBIN PAUL D | Executive Officer | Sell | 7,433 | $12.85 | $96K | SEC |
| Dec 11, 2025 | RUBIN PAUL D | Executive Officer | Sell | 18,000 | $12.00 | $216K | SEC |
| Dec 5, 2025 | RUBIN PAUL D | Executive Officer | Sell | 68,897 | $10.19 | $702K | SEC |
| Mar 10, 2025 | Hemrajani Rekha | Director | Buy | 3,000 | $18.00 | $54K | SEC |
| Mar 10, 2025 | Barton Shane | Officer | Buy | 2,632 | $18.00 | $47K | SEC |
In the last 12 months BioAge Labs, Inc. insiders made open-market purchases worth about $0 and sales worth about $7.8 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in BIOA was filed on 2026-07-01.
151 investment managers reported holding BIOA in SEC Form 13F filings for Q2 2026.
No congressional trades in BIOA were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).